Sanofi SA (SASY)

87.54
+0.54(+0.62%)
  • Volume:
    1,254,241
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    86.75 - 87.60

SASY Overview

Prev. Close
87
Day's Range
86.75-87.6
Revenue
44.76B
Open
86.77
52 wk Range
76.45-106.1
EPS
5.12
Volume
1,254,241
Market Cap
109.78B
Dividend (Yield)
3.33
(3.80%)
Average Volume (3m)
1,849,986
P/E Ratio
16.90
Beta
0.424
1-Year Change
1.56%
Shares Outstanding
1,254,059,666
Next Earnings Date
08 Feb 2023
What is your sentiment on Sanofi?
or
Market is currently closed. Voting is open during market hours.

Sanofi SA News

Sanofi SA Analysis

Sanofi SA Company Profile

Sanofi SA Company Profile

Employees
95442
Market
France
  • Type:Equity
  • Market:France
  • ISIN:FR0000120578

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Read More

Analyst Price Target

Average107.92 (+23.28% Upside)
High134
Low85
Price87.54
No. of Analysts25
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuySell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral
  • Will eventually do well because of French strategy. France is at the top table and Sanofi was made up by absorbing others to grow. Look at 20% in a couple of years
    0
    • there is no future for it
      9